Chemotherapy‐Induced Cardiotoxicity With Frontline BV‐AVD for Hodgkin Lymphoma
Angelo Rizzolo, Caroline Michel, Nathalie A Johnson, Jose I Mayordomo · 2025
Read Chemotherapy‐Induced Cardiotoxicity With Frontline BV‐AVD for Hodgkin Lymphoma by Angelo Rizzolo, Caroline Michel, Nathalie A Johnson, Jose I Mayordomo (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12747064.txt.
Description
Angelo Rizzolo and co-authors report heart damage appearing during a modern frontline regimen for Hodgkin lymphoma, in a paper from 2025. The regimen pairs an antibody drug conjugate with standard chemotherapy and works well against the cancer. Its known burdens are nerve damage and low white cell counts, watched for as a matter of routine.
Since the regimen spread into wider use, less expected harms have surfaced. The case described here involves injury to the heart muscle during treatment. The authors present the clinical course and argue for vigilant heart monitoring while patients receive the drug. They also call for research into who is at risk, how the injury happens, and how safe the therapy proves over the long term.
Catalog record
| CREATOR | Angelo Rizzolo, Caroline Michel, Nathalie A Johnson, Jose I Mayordomo |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 10 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |